Status:
COMPLETED
Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Triangle Pharmaceuticals
Gilead Sciences
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The combination of two nucleoside analogues and one protease inhibitor is a highly active antiretroviral therapy (HAART) in HIV infected adults. In those with an undetectable viral load, a once daily ...
Detailed Description
The combination of two nucleoside analogues and one protease inhibitor is a highly active antiretroviral therapy (HAART) in HIV infected adults, but side effects an the great number of pills induces l...
Eligibility Criteria
Inclusion
- HIV infected adults
- Antiretroviral treatment since 6 months, with two nucleoside analogues and one or two protease inhibitors
- CD4 cell count over 100/mm3
- HIV RNA below 400 copies/ml since 6 months
- Signed written informed consent
Exclusion
- Previous treatment with non nucleoside analogue, ddI alone
- Pregnancy
- Alcool abuse
- Acute infection, past neurological or pancreatic disease, biological abnormalities
- Chemotherapy or immunotherapy
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00196612
Start Date
April 1 2001
End Date
September 1 2004
Last Update
September 20 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.